LSKL is an inhibitor peptide composed of 4 amino acids. It is a peptide derived from a latency-related peptide, which can inhibit the activation of TGF-β thrombospondin (TSP-1) and prevent liver damage and fibrosis; at the same time, LSKL It can easily cross the blood-brain barrier and reduce hydrocephalus; LSKL can successfully reduce the activation of TGF-β-Smad signal by antagonizing TSP-1, but cannot reduce the protein expression of TSP-1; LSKL can also promote liver after hepatectomy Cell Proliferation.